GlassScriptPhysician profile
Brian D Gibson
NPI 1982802021
$2,433.77
in general payments reported to CMS, 2019-2025
24 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $346 · 2021: $271 · 2022: $282 · 2023: $464 · 2024: $395 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.01 |
| Education | $104.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $650.60 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $450.44 | 2021-2025 | Dupixent |
| Acclarent, INC | $224.05 | 2020-2023 | Trudi Nav Cable |
| Merck Sharp & Dohme LLC | $186.12 | 2019-2023 | Verquvo, Belsomra |
| Janssen Pharmaceuticals, INC | $155.39 | 2019-2021 | |
| Glaxosmithkline, LLC. | $130.44 | 2023-2025 | Nucala |
| Optinose US, INC. | $103.72 | 2019-2021 | |
| Amgen INC. | $95.48 | 2019-2025 | Otezla, Repatha |
| Medtronic, INC. | $75.80 | 2021-2024 | Propel |
| Sanofi-Aventis U.S. LLC | $52.99 | 2025 | |
| Novo Nordisk INC | $41.22 | 2024 | Ozempic, Wegovy |
| Kaleo, INC. | $35.23 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $34.14 | 2025 | Airsupra |
| Integra Lifesciences Corporation | $23.69 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.46 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $19.76 | 2023 | Inspire |
| Smith+Nephew, INC. | $19.37 | 2020 | |
| Stryker Corporation | $19.14 | 2020 | |
| Aerin Medical INC. | $18.44 | 2020 | |
| Intersect Ent, INC. | $16.87 | 2021 | |
| Scilex Pharmaceuticals INC. | $15.69 | 2019 | |
| Olympus America INC. | $14.93 | 2025 | Evis Exera III Video System Center |
| Hikma Pharmaceuticals USA | $14.20 | 2023 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.